AI assistant
Pacira BioSciences, Inc. — Director's Dealing 2014
Mar 7, 2014
32125_dirs_2014-03-06_455f6bb0-5041-4c27-805b-f3bce3eee872.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Pacira Pharmaceuticals, Inc. (PCRX)
CIK: 0001396814
Period of Report: 2014-03-05
Reporting Person: Wicki Andreas (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-03-05 | Common Stock | S | 22687 | $80.1627 | Disposed | 1669507 | Indirect |
| 2014-03-06 | Common Stock | S | 2200 | $80.1111 | Disposed | 1667307 | Indirect |
Footnotes
F1: The price reported in Column 4 is a weighted average price. Thses shares were sold in multiple transactions at prices ranging from $80.07 to $80.25, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote one (1) of this Form 4.
F2: The Board of Directors of HBM (the "HBM Board") has sole voting and investment power with respect to the securities held by such entity and acts by majority vote. The reporting person does not have sole voting or investment power over the securities held by HBM. However, the reporting person may be deemed to have beneficial ownership of these securities by virtue of his membership on the Board of HBM. The reporting person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1 (a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest herein, if any. This report on Form 4 shall not be deemed an admission that the rporting person is a beneficial owner for the purposes of Section 16 of the Exchange Act, or for any other purpose of Section 16 of the Exchange Act, or for any other purpose.
F3: The price reported in Column 4 is a weighted average price. Thses shares were sold in multiple transactions at prices ranging from $80.07 to $80.55, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote three (3) of this Form 4.